Cardioprotective Effect of Dexmedetomidine in Patients With ST-segment Elevation Myocardial Infarction: a Double-Blind, Multicenter, Randomized, Placebo-Controlled Clinical Trial

What this Trial Is About

Researchers are evaluating the effects of dexmedetomidine (DEX) on heart damage size in patients who have experienced an anterior ST-segment elevation myocardial infarction (STEMI) and are undergoing primary percutaneous coronary intervention (pPCI) within 6 hours of symptom onset. This double-blind, randomized, placebo-controlled trial aims to determine if DEX can reduce myocardial infarct size compared to a placebo. The trial plans to enroll 250 patients to achieve reliable results. Participants are randomly assigned to either the DEX group or the placebo group in a 1:1 ratio. Those in the DEX group receive an intravenous infusion starting immediately upon enrollment, with doses adjusted between 0.2 to 0.7 µg/kg/h based on heart rate, blood pressure, and sedation scores, continuing throughout the PCI procedure. The placebo group receives saline infusions following the same schedule and dose adjustments. This treatment phase occurs during the PCI operation. During the study, patients undergo cardiac magnetic resonance imaging (CMR) about 5 days after STEMI to measure myocardial infarct size and other heart function indicators. Additional evaluations include blood tests for heart damage markers at multiple time points after PCI and echocardiography at 30 days. Researchers track major adverse cardiovascular events up to 12 months post-STEMI. Total participation includes initial treatment and follow-up assessments over one year.

Cardioprotective Effect of Dexmedetomidine in Patients With ST-segment Elevation Myocardial Infarction